Ruxolitinib cream highly effective in treatment of cutaneous lichen planus: Study

Arizona: Topical ruxolitinib is highly effective for treating cutaneous lichen planus (LP), according to findings from a small pilot study in the Journal of Investigative Dermatology. The transcriptomic analysis provided confirmation of LP being an interferon-driven disease and the downregulation of interferon-stimulated genes (ISGs) corresponds to disease response. 

Lichen planus is an inflammatory skin condition that affects the skin and mucosal surfaces. Cutaneous lichen planus is a clinical type of lichen planus that shares similar features on histopathology. Its symptoms can range from none (uncommon) to intense itch.

Ruxolitinib is an inhibitor of Janus kinase 1/2 that blocks signal transduction of a critical cytokine involved in the pathogenesis of cutaneous LP called interferon-gamma. In the prospective phase II study, Aaron R. Mangold, Department of Dermatology, Mayo Clinic Arizona, and colleagues investigated the efficacy of topical ruxolitinib in cutaneous LP and performed transcriptomic analysis pre-and post-therapy.  

The study included 12 patients with cutaneous LP who were applied topical ruxolitinib twice daily for 8 weeks. Primary endpoints were changes in total lesion count and modified Composite Assessment of Index Lesion Severity (mCAILS) score in index treated and untreated index control lesions at week 4. 

"Findings revealed that topical ruxolitinib is highly effective in the treatment of cutaneous LP," wrote the authors. "Transcriptomic analysis confirmed LP as an interferon-driven disease and downregulation of ISGs correlated with disease response."

Reference:

The study titled, "Ruxolitinib cream in the treatment of cutaneous lichen planus: A prospective, open-label study," was published in the Journal of Investigative Dermatology.

DOI: https://doi.org/10.1016/j.jid.2022.01.015